Ocuphire Pharma, Inc. (OCUP) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Farmington Hills, MI, United States. The current CEO is George Magrath.
OCUP has IPO date of 2005-11-10, 14 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $31.74M.
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
